The CRO is adding two new offices in the US to support what has been significant growth over the past several years from pharma and biotech customers working in rare diseases and immune-oncology.
Cryoport is supporting a record number of clinical trials driven by rapid growth in regenerative medicine – a space that will continue to grow and outpace the pharmaceutical industry, says CCO.